ARCH Venture Management
ARCH Venture Management reported 17 stocks worth $1.6B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KARD (13.8%), PBLS (12.8%) and VIR (8.8%). Compared with Q2 2026, the fund opened new positions in KARD, SANA and SRRK and sold out of TXG and GOSS.
Latest filing: what ARCH Venture Management did in Q3 2026
vs Q2 2026None
None
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() KARD Kardigan Inc | $222M | 13.8% | 15M | New position | 1 of 8 | |
| 2 | ![]() PBLS Parabilis Medicines Inc Com | $207M | 12.8% | 6.4M | No change | 2 of 8 | |
| 3 | ![]() VIR Vir Biotechnology Inc | $142M | 8.8% | 12.7M | No change | 6 of 8 | |
| 4 | ![]() SANA Sana Biotechnology Inc | $134M | 8.3% | 45.9M | New position | 1 of 8 | |
| 5 | ![]() SPTX Seaport Therapeutics Inc | $127M | 7.9% | 6.3M | No change | 2 of 8 | |
| 6 | ![]() RAPP Rapport Therapeutics Inc | $125M | 7.8% | 3.7M | No change | 8 of 8 | |
| 7 | ![]() SRRK Scholar Rock Hldg Corp | $113M | 7.0% | 2.3M | New position | 1 of 8 | |
| 8 | ![]() MAZE Maze Therapeutics Inc | $112M | 6.9% | 4.1M | No change | 7 of 8 | |
| 9 | ![]() BEAM Beam Therapeutics Inc | $111M | 6.9% | 4.5M | No change | 8 of 8 | |
| 10 | ![]() ERAS Erasca Inc | $104M | 6.4% | 7.1M | No change | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →ARCH Venture Management 13F FAQ
What does ARCH Venture Management own?
ARCH Venture Management reported 17 stocks worth $1.6B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KARD (13.8%), PBLS (12.8%) and VIR (8.8%). The table above lists every position in the filing (the top 10 without an account).
What did ARCH Venture Management buy and sell in Q3 2026?
Compared with Q2 2026: 7 new positions, 0 added to, 0 trimmed and 2 sold out. New positions include KARD, SANA and SRRK. It sold all of TXG and GOSS.
When will ARCH Venture Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is ARCH Venture Management's portfolio worth?
The Q3 2026 filing reports $1.6B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.













